证券之星消息，9月26日医疗服务板块较上一交易日下跌2.73%，皓宸医疗领跌。当日上证指数报收于 3828.11，下跌0.65%。深证成指报收于13209.0，下跌1.76%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301333 | 诺思格 | 53.46 | 1.02% | 3.80万 | | 2.08亿 | | 002524 | 光正眼科 | 4.30 | 0.70% | 11.78万 | 5037.04万 | | | 000504 | *ST生物 | 9.32 | 0.22% | + 1.37万 | 1273.79万 | | | 600763 | 通策医疗 | 43.85 | -0.18% | 7.40万 | | 3.23亿 | | 688131 | 皓元医药 | 79.22 | -0.20% | 5.48万 | | 4.31亿 | | 301201 | 诚达药业 | 29.71 | -0.27% | 3.48万 | | 1.03亿 | ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-021 一、债权人变更情况 1、债务基本情况 公司于 2020 年 6 月 8 日召开第四届董事会第三十一次临时会议以及 2020 年 6 月 23 日召开的 2020 年第一次临时股东大会审议通过《关于向温州银行股份有限 公司申请贷款并提供担保的议案》，同意公司向温州银行股份有限公司申请贷款， 申请贷款金额不超过人民币 2 亿元，贷款期限为 12 个月。根据温州银行股份有限 公司向公司发送的通知，其将编号为[733002020 企贷字 00151 号]的《温州银行非 自然人借款合同》及其补充协议项下的债权及全部从权利转让给浙商资管，浙商 资管已取得债权人的地位，有权行使债权人享有的各项权利。公司与浙商资管、 温州银行股份有限公司签署了《债务确认及分期还款协议》，公司将在两年时间内 分期归还 17,349.00 万元本金并于 2023 年 12 月 20 日到期日前一次归还全部利息。 截至目前，公司尚欠贷款本金 95,745,681.88 元。 因与浙商资管、温州银行股份有限公司之间部分银行借款纠纷事项，浙商资 管向北京市第一中级人民法院申请强制 ...

Group 1 - The company, Haocen Medical, has received a debt transfer notification and a lawyer's letter regarding the transfer of debts from Zhejiang Zheshang Asset Management Co., Ltd. to Zhejiang Zheba Xianhu Enterprise Management Partnership (Limited Partnership) [1][2] - The debt transfer agreement was signed on September 10, 2025, and includes all rights related to the principal debt, secured debt, penalty debt, interest debt, and compensation rights [2] - The new creditor, Zhejiang Zheba Xianhu Enterprise Management Partnership, is demanding that Haocen Medical and its guarantors fulfill their payment obligations as per the relevant legal documents from the date of the announcement [2]

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

Group 1 - The stock price of Haocen Medical (002622) closed at 3.94 yuan on September 3, 2025, with an increase of 3.96% and a trading volume of 706,500 hands, resulting in a transaction amount of 274 million yuan [1] - On September 3, 2025, the net inflow of main funds was 8.9685 million yuan, accounting for 3.27% of the total transaction amount, while retail investors experienced a net outflow of 36.7847 million yuan, representing 13.42% of the total transaction amount [1] - The company's main business includes oral medical services and the research, production, and sales of permanent magnet switches and complete sets of high and low voltage switchgear [2] Group 2 - Haocen Medical's total market value is 3.31 billion yuan, with a net asset of 408 million yuan and a net profit of -23.7511 million yuan, ranking 37th, 39th, and 36th respectively in the medical service industry [2] - The company's revenue for the first half of 2025 was 314 million yuan, a year-on-year decrease of 17.9%, while the net profit attributable to shareholders was -23.7511 million yuan, a year-on-year decline of 4391.18% [2] - The gross profit margin of Haocen Medical is 43.16%, which is higher than the industry average of 35.92%, while the net profit margin is -11.04%, significantly lower than the industry average of 3.8% [2]

Core Points - The company has released its 2025 semi-annual report, which provides insights into its operational results, financial status, and future development plans [1] - The board of directors and the supervisory board have both approved the semi-annual report, confirming that the content is true, accurate, and complete [12][13] Company Overview - The company is named Haocen Medical Technology Co., Ltd., with the stock code 002622 [1] - The company has not changed its controlling shareholder during the reporting period [5] Financial Information - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [3] - The company has confirmed that there are no preferred shareholders or changes in preferred shareholder holdings during the reporting period [6] Meeting Details - The fifth board of directors' fifteenth meeting was held on August 28, 2025, with all directors present [2][7] - The supervisory board's fifteenth meeting was also held on August 28, 2025, with all supervisors present [12][13] Document Availability - The full content of the 2025 semi-annual report can be accessed on the designated information disclosure website [9][14]

Financial Performance - The company's total revenue for the first half of 2025 was 314 million yuan, ranking 39th among disclosed peers, representing a decrease of 68.37 million yuan or 17.90% year-on-year [1] - The net profit attributable to shareholders was -23.75 million yuan, ranking 44th among disclosed peers, a decrease of 24.30 million yuan or 4391.18% year-on-year [1] - The net cash flow from operating activities was -27.59 million yuan, ranking 43rd among disclosed peers, a decrease of 34.59 million yuan or 494.15% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio was 71.73%, ranking 47th among disclosed peers, an increase of 0.64 percentage points from the previous quarter and 2.00 percentage points year-on-year [3] - The latest gross profit margin was 43.16%, ranking 18th among disclosed peers, an increase of 4.65 percentage points from the previous quarter but a decrease of 2.90 percentage points year-on-year [3] - The latest return on equity (ROE) was -6.37%, ranking 48th among disclosed peers, a decrease of 6.50 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share was -0.03 yuan, ranking 41st among disclosed peers, a decrease of 0.03 yuan or 4142.86% year-on-year [3] - The latest total asset turnover ratio was 0.21 times, ranking 25th among disclosed peers, a decrease of 0.03 times or 13.82% year-on-year [3] - The latest inventory turnover ratio was 3.43 times, ranking 23rd among disclosed peers, an increase of 0.16 times, marking five consecutive years of growth, and an increase of 4.91% year-on-year [3]

Group 1 - The company Haocen Medical (SZ 002622) announced the convening of its fifth board meeting on August 28, 2025, which was held in a hybrid format combining in-person and remote voting [1] - The meeting reviewed the proposal regarding the full text and summary of the 2025 semi-annual report [1] Group 2 - The article mentions that over 20,000 applications have been submitted for joining Haidilao, with 41 franchises already opened, indicating strong interest in the brand [1] - The estimated investment required to join Haidilao is around 10 million yuan, which is considered not excessive [1]

Core Viewpoint - Haocen Medical (002622.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 314 million yuan, representing a year-on-year decrease of 17.90% [1] - The net profit attributable to shareholders of the listed company was -23.75 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -23.56 million yuan [1] - The basic earnings per share were -0.0283 yuan [1]

皓宸医疗科技股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 | 非经营性资金占用 | 资金占用 | 占用方与上 | 上市公司 | 年 2025 | 年 月占 2025 1-6 | | 年 月 2025 1-6 | | 年 2025 1-6 | | 年 月 2025 6 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方名称 | 市公司的关 | 核算的会 | 期初占用 | 用累计发生金额 | | 占用资金的利 | | 月偿还累计 | 30 | 日占用资 | 成原因 | 占用性质 | | | | 联关系 | 计科目 | 资金余额 | （不含利息） | | 息（如有） | | 发生金额 | | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | ...